New trials, publications, preprints and grants on this target, month by month.
Trial
Evaluate the Safety and Tolerability of CE211NS21 in Patients With AQP4-IgG-positive NMOSD Relapse
1 Dec 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
The Balance Between Immune Activation and Tolerance in AQP4 Antibody-Positive Neuromyelitis Optica Spectrum Disorders and MOG Antibody-Associated Disease.
22 Oct 2026· Immunology and cell biology· PUBMED
Publication
Investigation of Complement Activation and Cytokine Signatures in AQP4+ NMOSD, MOGAD, and MS.
21 Oct 2026· Annals of clinical and translational neurology· PUBMED
Publication
Phase-associated differences in perivascular and glymphatic-related MRI markers in AQP4-IgG-seropositive neuromyelitis Optica spectrum disorder: A cross-sectional study.
21 Oct 2026· Multiple sclerosis and related disorders· PUBMED
Publication
Progressive hemifacial atrophy, AQP4-positive NMOSD and suspected Sjögren's syndrome: five-year relapse-free follow-up during rituximab therapy.
21 Oct 2026· Acta neurologica Belgica· PUBMED
Publication
Differential Trajectories of Brain Atrophy in Multiple Sclerosis, MOGAD, and AQP4 + NMOSD: The Role of Disease Activity in MOGAD.
20 Oct 2026· Neurology· PUBMED
Publication
AQP4 antibody-induced astrocyte injury reshapes CNS immune architecture in a combined EAE-AQP4-IgG model of neuromyelitis optica spectrum disorder.
19 Oct 2026· Frontiers in immunology· PUBMED
Publication
Autoimmune comorbidity profiles in MOGAD and AQP4-NMOSD: a real-world evidence study of top 10 autoimmune disorders across the pre- and post-COVID-19 eras.
17 Oct 2026· Multiple sclerosis and related disorders· PUBMED
Publication
Characterization of distinct cognitive domain patterns in AQP4-IgG-positive NMOSD: A MoCA-based factor analysis and risk profiling.
17 Oct 2026· Multiple sclerosis and related disorders· PUBMED
Publication
Clinical phenotype and treatment response in AQP4-IgG-positive NMOSD and MOGAD: insights from the Italian I-MS&RD registry.
16 Oct 2026· Journal of neurology· PUBMED
Publication
Cerebral Attack With Cortical-Leptomeningeal Involvement and Seizures in AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
15 Oct 2026· Internal medicine (Tokyo, Japan)· PUBMED
Publication
Astrocytic and Axonal Injury Biomarkers in AQP4 Antibody-Positive NMOSD: Insights From PREVENT and CHAMPION-NMOSD.
8 Oct 2026· Neurology(R) neuroimmunology & neuroinflammation· PUBMED
Publication
Efficacy and Safety of Multidisciplinary Sandwich Regimen in AQP4-IgG+ NMOSD With Preconception B-Cell Depletion During Perigravidity.
1 Oct 2026· CNS neuroscience & therapeutics· PUBMED
Publication
Serum GFAP and Age Accurately Distinguish AQP4-IgG Positive and Double Seronegative NMOSD From MOGAD After a Recent Attack.
1 Oct 2026· European journal of neurology· PUBMED
Publication
Why repair fails in AQP4-IgG-positive neuromyelitis optica spectrum disease: an astrocyte-centered framework for remyelination and neuroaxonal preservation.
29 Sept 2026· Frontiers in immunology· PUBMED
Publication
Case Report: Unplanned pregnancy during treatment with inebilizumab in patients with AQP4-IgG-seropositive NMOSD: report of two cases.
24 Sept 2026· Frontiers in immunology· PUBMED
Publication
Diagnostic Utility of Novel and Established Spinal MRI Signs in AQP4-IgG-Seropositive NMOSD Myelitis.
21 Sept 2026· Neurology· PUBMED
Publication
Optimizing the management of AQP4 antibody-positive NMOSD: A Canadian consensus.
21 Sept 2026· Multiple sclerosis and related disorders· PUBMED
Publication
Scutellarin attenuates high glucose-induced edema and inflammation in retinal Müller cells via AQP4/Kir4.1 restoration and TLR4/MyD88/NF-κB inhibition.
18 Sept 2026· Frontiers in pharmacology· PUBMED
Publication
Comparative effectiveness of inebilizumab versus conventional immunotherapies in AQP4-IgG-positive NMOSD: a prospective cohort study with time-varying treatment effects.
15 Sept 2026· Journal of neurology, neurosurgery, and psychiatry· PUBMED
Publication
Inter-attack serum GFAP and NfL remain stable over 9 years in AQP4 IgG NMOSD.
14 Sept 2026· Journal of neurology, neurosurgery, and psychiatry· PUBMED
Trial
A Safety and Tolerability Study of CC- 97540 (BMS-086353) in Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Patients
1 Sept 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publication
IL-6 Receptor Blockade as Rescue Therapy in Acute Attacks of MOGAD and AQP4+NMOSD.
1 Sept 2026· JAMA neurology· PUBMED
Publication
Multimodal assessment of sleep and regional brain volumes in AQP4-IgG-positive neuromyelitis optica spectrum disorder: An exploratory cross-sectional study.
27 Aug 2026· Multiple sclerosis and related disorders· PUBMED
Publication
Inebilizumab in AQP4-Seropositive NMOSD: One-Year Follow-Up From a Multicenter, Real-World Study.
23 Aug 2026· Annals of clinical and translational neurology· PUBMED
Publication
A systematic review and meta-analysis of the efficacy and safety of eculizumab in AQP4-IgG-positive neuromyelitis optica spectrum disorder.
22 Aug 2026· Multiple sclerosis and related disorders· PUBMED
Publication
Clinical Significance and Changes in Levels of Serum BDNF, mBDNF, AQP4, proBDNF, and GSK3β in Individuals Diagnosed With Bipolar Disorder: A Cross-Sectional Study.
11 Aug 2026· Health science reports· PUBMED
Publication
Clinical and serological features of systemic autoimmune overlap in AQP4-IgG positive neuromyelitis optica spectrum disorder: a Mexican cohort study.
4 Aug 2026· Multiple sclerosis and related disorders· PUBMED
Preprint
2,6-diaminopurine enhances Aqp4 stop codon readthrough and AQP4 perivascular localization in the brain.
4 Aug 2026· bioRxiv : the preprint server for biology· PUBMED
Publication
Ravulizumab rescue therapy in a refractory AQP4-positive neuromyelitis optica attack with extensive encephalomyelitis.
3 Aug 2026· Revue neurologique· PUBMED